Note 8 - Notes, Loans and Financing (Details) - Loan Agreements (USD $) In Thousands, unless otherwise specified	Jun. 30, 2013		Dec. 31, 2012
Loan Agreements [Abstract]
May 2011 senior secured term loan due May 27, 2014 (1)	$ 4,071	[1]	$ 4,071	[1]
Total notes and loans payable, before debt discount	4,071		4,071
Less: Debt discount	(31)		(96)
Total notes and loans payable	4,040		3,975
Notes and loans payable, current portion	4,040		3,975
Notes and loans payable, long-term	$ 0		$ 0

[1] The Company entered into a senior secured term loan in the amount of $8.6 million with Midcap in May 2011. The Company had the option to borrow an additional $2.0 million from Midcap on or before December 31, 2011 upon meeting certain conditions, including the commencement of a Phase III clinical trial, which it did not exercise. The interest rate on the loan is 11.5% per year. The Company incurred approximately $0.1 million in issuance costs in connection with the loan and is required to pay a $0.3 million fee on the maturity date of the loan. In addition, the Company issued five year common stock purchase warrants to Midcap granting them the right to purchase 1.1 million shares of the Company's common stock at an exercise price of $0.63 per share. The basic terms of the loan require monthly payments of interest only through November 1, 2011, with 30 monthly payments of principal and interest that commenced on December 1, 2011. Any outstanding balance of the loan and accrued interest is to be repaid on May 27, 2014. In connection with the terms of the loan agreement, the Company granted Midcap a security interest in substantially all of the Company's personal property including its intellectual property.